JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Arrowhead Pharmaceuticals Inc

Fechado

SetorSaúde

37.97 1.55

Visão Geral

Variação de preço das ações

24h

Atual

Mín

37.54

Máximo

38.05

Indicadores-chave

By Trading Economics

Rendimento

-547M

-179M

Vendas

-515M

28M

Margem de lucro

-643.397

Funcionários

609

EBITDA

-546M

-148M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+11.66% upside

Dividendos

By Dow Jones

Próximos Ganhos

25 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3B

5.3B

Abertura anterior

36.42

Fecho anterior

37.97

Sentimento de Notícias

By Acuity

22%

78%

42 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Arrowhead Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de out. de 2025, 18:41 UTC

Ganhos

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 de out. de 2025, 18:31 UTC

Ganhos

Correction to Procter & Gamble to Focus on Innovation

24 de out. de 2025, 16:25 UTC

Grandes Movimentos do Mercado

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de out. de 2025, 21:24 UTC

Conversa de Mercado

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 de out. de 2025, 21:07 UTC

Ganhos

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 de out. de 2025, 20:58 UTC

Ganhos

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 de out. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 20:40 UTC

Ganhos

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 de out. de 2025, 20:24 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:23 UTC

Ganhos

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 de out. de 2025, 20:13 UTC

Ganhos

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 20:07 UTC

Conversa de Mercado

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 de out. de 2025, 19:40 UTC

Conversa de Mercado

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 de out. de 2025, 19:35 UTC

Conversa de Mercado

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 de out. de 2025, 19:33 UTC

Ganhos

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 de out. de 2025, 19:29 UTC

Conversa de Mercado

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 de out. de 2025, 18:52 UTC

Ganhos

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:41 UTC

Ganhos

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 de out. de 2025, 18:03 UTC

Ganhos

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 de out. de 2025, 18:02 UTC

Ganhos

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 de out. de 2025, 18:00 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 de out. de 2025, 16:57 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 de out. de 2025, 16:54 UTC

Conversa de Mercado

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 de out. de 2025, 16:44 UTC

Conversa de Mercado
Ganhos

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 de out. de 2025, 16:39 UTC

Conversa de Mercado
Ganhos

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 de out. de 2025, 16:33 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:23 UTC

Ganhos

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 de out. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de out. de 2025, 16:07 UTC

Ganhos

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Comparação entre Pares

Variação de preço

Arrowhead Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

11.66% parte superior

Previsão para 12 meses

Média 42.43 USD  11.66%

Máximo 80 USD

Mínimo 17 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

6

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

11.5 / 12.23Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

42 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
help-icon Live chat